{'fraction_non_alphanumeric': 0.03146551724137931, 'fraction_numerical': 0.030603448275862068, 'mean_word_length': 5.556497175141243, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clinicopathologic features of patients with breast cancer under teatment of bisphosphonate at the time of diagnosis: Retrospective analysis.

e11016 Background: Addition of zolderonic acid to neoadjuvant chemotherapy provided a significant tumor shrinkage compared to neoadjuvant chemotherapy alone was shown in AZURE trial. We aimed to compare the clinicopathological features of breast cancer patients under treatment of bisphophonates due to osteoporosis with an age match control group, retrospectively.


METHODS
The data of 1127 patients followed at our center between years 2004 - 2009 were analyzed retrospectively. Patients were taking bisphosphonates at least for 6 months (n=35) and never used bisphoshonates (n=140) were matched according to age. Median age at diagnosis, histopathological parameters, and menopausal status were analysed.


RESULTS
A nuber of 175 patients were included to the study. Median age of diagnosis was 57 (min-max: 33-77). Median ages were similar in patients bisphosphate receiving or not. The number of patients at stage T1 were higher in bisphosphonate teated group than not treated (42,4 vs 24,6%, p=0,12). Similarly, number of patients at stage N3 were lower in bisphosphonate receiving compared to none receiving (5,9 vs 18,3%, p=0.13). Number of patients at stage III and IV were higher in bisphosphonateun-treated (41,4 vs 33,4%, p=0.42). Estrogen receptor (ER) positivity were more frequent in oral bisphosphonate treated group (87,9 vs 69,4, p=0.047). There were no statistical differences in menopausal status at the time of diagnosis, histopathological subtypes and grade, lymphovascular and perineural invasion, extracapsular extension, progesteron and HER2 receptor positivity and body weights between groups receiving bisphosphonates or not.


CONCLUSIONS
Breast cancer patients receiving oral bisphosphonates due to osteoporosis were shown to be diagnosed at earlier stages. This finding might be related with more frequent participation of oral bisphosphonate receiving patients to screening programs and aggravation of soft tissue calcification due to bisphosphonates. Furthermore question remains about the higher frequency of ER positivity in bisphosphonate receiving patients if it was related with bisphosphonate treatment or etiopathogenesis of osteoporosis.